Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study

There are very few studies evaluating lipid-lowering treatments (LLTs) and low-density lipoprotein-cholesterol (LDL-C) goal attainment after the release of the 2019 guidelines of the European Societies of Cardiology (ESC) and Atherosclerosis (EAS). This manuscript shows baseline data of the Spanish...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista clínica espanõla (English edition) 2024-11
Hauptverfasser: Mostaza, J.M., García-Ortiz, L., Suárez Tembra, M.A., Talavera Calle, P., Chimeno García, J., Escolar Pérez, V., Díaz-Díaz, J.L., Manzano-Espinosa, L., Catapano, A.L., Ray, K.K., Díaz Moya, G., Pedro-Botet Montoya, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Revista clínica espanõla (English edition)
container_volume
creator Mostaza, J.M.
García-Ortiz, L.
Suárez Tembra, M.A.
Talavera Calle, P.
Chimeno García, J.
Escolar Pérez, V.
Díaz-Díaz, J.L.
Manzano-Espinosa, L.
Catapano, A.L.
Ray, K.K.
Díaz Moya, G.
Pedro-Botet Montoya, J.
description There are very few studies evaluating lipid-lowering treatments (LLTs) and low-density lipoprotein-cholesterol (LDL-C) goal attainment after the release of the 2019 guidelines of the European Societies of Cardiology (ESC) and Atherosclerosis (EAS). This manuscript shows baseline data of the Spanish subset from SANTORINI study (namely SANTORINI Spain) on LDL-C goal attainment and use of LLTs in patients at high and very high cardiovascular risk. SANTORINI was a multinational, prospective, observational study involving patients at high and very high cardiovascular risk from 14 European countries in primary care and specialized healthcare settings. Sociodemographic data, blood lipid levels, and lipid treatments from the 1018 Spanish participants were separately analyzed and were put into perspective with the European cohort without Spanish participants. According to physicians, 295 (29.0%) subjects were classified as high, and 723 (71.0%) as very high cardiovascular risk. Overall, 26.5% attained risk-based LDL-C targets recommended by 2019 European guidelines, with 23.1% of patients at high cardiovascular risk and 27.9% at very high cardiovascular risk. High-intensity statin therapy in monotherapy was used in 21.8%, LLT combination therapy in 41.2%, and 10.7% were not receiving any LLT. Baseline data from SANTORINI Spain population show that only about one-fourth of patients attain LDL-C targets recommended by the 2019 ESC/EAS guidelines in patients at high and very high risk. Despite their cardiovascular risk, patients appear to be not adequately treated, and high-intensity and combination LLT seem to be underused for cardiovascular disease prevention in the real-world setting. ClinicalTrials.gov Identifier: NCT04271280. Existen pocos estudios que hayan evaluado el tratamiento hipolipemiante (LLTs) y la consecución de objetivos de colesterol de lipoproteínas de baja densidad (C-LDL) después de la publicación de las guías de 2019 de la Sociedad Europea de Cardiología (ESC) y Aterosclerosis (EAS). Este manuscrito presenta los datos basales de la subpoblación española del estudio SANTORINI (denominado SANTORINI España) sobre la consecución de objetivos de LDL-C y el uso de LLTs en pacientes con riesgo cardiovascular alto y muy alto. SANTORINI fue un estudio multinacional, prospectivo y observacional que incluyó a pacientes con riesgo cardiovascular alto y muy alto de 14 países europeos en entornos de atención primaria y atención especializada. En el presente an
doi_str_mv 10.1016/j.rceng.2024.11.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3134330681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2254887424001504</els_id><sourcerecordid>3134330681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1540-d8e4e6551a4251f3ca0ff47501080b7921c1c5d1fe5a2f4a4d0722f47dd69f273</originalsourceid><addsrcrecordid>eNp9kd1uEzEQhVcIRKvSJ0BCvuRmF4_X-xMkLqr0h0hRK9FybTn2OOuwWS_2OijPxQvWSQriiquZkb5zZuyTZe-BFkCh_rQpvMJhXTDKeAFQUMpfZeeMVTxv24a__qc_yy5D2FBKgcGsqunb7Kyc1VACpefZ71tp--iROEOW18t8TtZO9oFI1Vnc4RaHichBkzho9DEcud6OVue9-4XeDmsydejlaDEQO5BRTjZpksFEOrvujuId-v1pUtJr63YyqNhLT7wNPz6Tx1EONnQkxFXAiRjvtgdTchO9G1EO5PHq_unh2-J-QcIU9f5d9sakG_HypV5k329vnuZf8-XD3WJ-tcwVVJzmukWOdVWB5KwCUypJjeFNRYG2dNXMGChQlQaDlWSGS65pw1LTaF3PDGvKi-zjyXf07mfEMImtDQr7Xg7oYhAllLwsad1CQssTqrwLwaMRo7db6fcCqDgEJjbiGJg4BCYARAosqT68LIirLeq_mj_xJODLCcD0zJ1FL4JK36tQW49qEtrZ_y54Br8PqWc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3134330681</pqid></control><display><type>article</type><title>Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study</title><source>Alma/SFX Local Collection</source><creator>Mostaza, J.M. ; García-Ortiz, L. ; Suárez Tembra, M.A. ; Talavera Calle, P. ; Chimeno García, J. ; Escolar Pérez, V. ; Díaz-Díaz, J.L. ; Manzano-Espinosa, L. ; Catapano, A.L. ; Ray, K.K. ; Díaz Moya, G. ; Pedro-Botet Montoya, J.</creator><creatorcontrib>Mostaza, J.M. ; García-Ortiz, L. ; Suárez Tembra, M.A. ; Talavera Calle, P. ; Chimeno García, J. ; Escolar Pérez, V. ; Díaz-Díaz, J.L. ; Manzano-Espinosa, L. ; Catapano, A.L. ; Ray, K.K. ; Díaz Moya, G. ; Pedro-Botet Montoya, J. ; en representación del grupo de investigadores de SANTORINI España</creatorcontrib><description>There are very few studies evaluating lipid-lowering treatments (LLTs) and low-density lipoprotein-cholesterol (LDL-C) goal attainment after the release of the 2019 guidelines of the European Societies of Cardiology (ESC) and Atherosclerosis (EAS). This manuscript shows baseline data of the Spanish subset from SANTORINI study (namely SANTORINI Spain) on LDL-C goal attainment and use of LLTs in patients at high and very high cardiovascular risk. SANTORINI was a multinational, prospective, observational study involving patients at high and very high cardiovascular risk from 14 European countries in primary care and specialized healthcare settings. Sociodemographic data, blood lipid levels, and lipid treatments from the 1018 Spanish participants were separately analyzed and were put into perspective with the European cohort without Spanish participants. According to physicians, 295 (29.0%) subjects were classified as high, and 723 (71.0%) as very high cardiovascular risk. Overall, 26.5% attained risk-based LDL-C targets recommended by 2019 European guidelines, with 23.1% of patients at high cardiovascular risk and 27.9% at very high cardiovascular risk. High-intensity statin therapy in monotherapy was used in 21.8%, LLT combination therapy in 41.2%, and 10.7% were not receiving any LLT. Baseline data from SANTORINI Spain population show that only about one-fourth of patients attain LDL-C targets recommended by the 2019 ESC/EAS guidelines in patients at high and very high risk. Despite their cardiovascular risk, patients appear to be not adequately treated, and high-intensity and combination LLT seem to be underused for cardiovascular disease prevention in the real-world setting. ClinicalTrials.gov Identifier: NCT04271280. Existen pocos estudios que hayan evaluado el tratamiento hipolipemiante (LLTs) y la consecución de objetivos de colesterol de lipoproteínas de baja densidad (C-LDL) después de la publicación de las guías de 2019 de la Sociedad Europea de Cardiología (ESC) y Aterosclerosis (EAS). Este manuscrito presenta los datos basales de la subpoblación española del estudio SANTORINI (denominado SANTORINI España) sobre la consecución de objetivos de LDL-C y el uso de LLTs en pacientes con riesgo cardiovascular alto y muy alto. SANTORINI fue un estudio multinacional, prospectivo y observacional que incluyó a pacientes con riesgo cardiovascular alto y muy alto de 14 países europeos en entornos de atención primaria y atención especializada. En el presente análisis se han analizado datos sociodemográficos, niveles de lípidos en sangre y tratamientos hipolipemiantes utilizados, en los 1018 participantes españoles, y se han puesto en perspectiva con la cohorte europea excluida la población española. Según el criterio de los médicos participantes, 295 (29,0%) pacientes fueron clasificados como de riesgo cardiovascular alto y 723 (71,0%) como de riesgo muy alto. Globalmente, el 26,5% alcanzó los objetivos de C-LDL recomendados por las guías europeas de 2019, un 23,1% de los pacientes con riesgo cardiovascular alto y un 27,9% de aquellos con riesgo cardiovascular muy alto. El tratamiento con estatinas de alta intensidad en monoterapia se utilizó en el 21,8%, la terapia combinada de hipolipemiantes en el 41,2%, y el 10,7% no recibió ningún LLT. Los datos basales de la población de SANTORINI España muestran que solo alrededor de una cuarta parte de los pacientes alcanza los objetivos de C-LDL recomendados por las guías ESC/EAS de 2019 en pacientes con riesgo cardiovascular alto y muy alto. A pesar de dicho riesgo, la utilización de tratamientos de alta intensidad y de tratamientos en combinación están infrautilizados. ClinicalTrials.gov: NCT04271280.</description><identifier>ISSN: 2254-8874</identifier><identifier>EISSN: 2254-8874</identifier><identifier>DOI: 10.1016/j.rceng.2024.11.004</identifier><identifier>PMID: 39613100</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Cardiovascular ; Colesterol de lipoproteínas de baja densidad ; España ; Lipid-lowering therapy ; Low-density lipoprotein cholesterol ; Riesgo ; Risk ; SANTORINI ; Spain ; Terapia hipolipemiante</subject><ispartof>Revista clínica espanõla (English edition), 2024-11</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier España, S.L.U. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1540-d8e4e6551a4251f3ca0ff47501080b7921c1c5d1fe5a2f4a4d0722f47dd69f273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39613100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mostaza, J.M.</creatorcontrib><creatorcontrib>García-Ortiz, L.</creatorcontrib><creatorcontrib>Suárez Tembra, M.A.</creatorcontrib><creatorcontrib>Talavera Calle, P.</creatorcontrib><creatorcontrib>Chimeno García, J.</creatorcontrib><creatorcontrib>Escolar Pérez, V.</creatorcontrib><creatorcontrib>Díaz-Díaz, J.L.</creatorcontrib><creatorcontrib>Manzano-Espinosa, L.</creatorcontrib><creatorcontrib>Catapano, A.L.</creatorcontrib><creatorcontrib>Ray, K.K.</creatorcontrib><creatorcontrib>Díaz Moya, G.</creatorcontrib><creatorcontrib>Pedro-Botet Montoya, J.</creatorcontrib><creatorcontrib>en representación del grupo de investigadores de SANTORINI España</creatorcontrib><title>Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study</title><title>Revista clínica espanõla (English edition)</title><addtitle>Rev Clin Esp (Barc)</addtitle><description>There are very few studies evaluating lipid-lowering treatments (LLTs) and low-density lipoprotein-cholesterol (LDL-C) goal attainment after the release of the 2019 guidelines of the European Societies of Cardiology (ESC) and Atherosclerosis (EAS). This manuscript shows baseline data of the Spanish subset from SANTORINI study (namely SANTORINI Spain) on LDL-C goal attainment and use of LLTs in patients at high and very high cardiovascular risk. SANTORINI was a multinational, prospective, observational study involving patients at high and very high cardiovascular risk from 14 European countries in primary care and specialized healthcare settings. Sociodemographic data, blood lipid levels, and lipid treatments from the 1018 Spanish participants were separately analyzed and were put into perspective with the European cohort without Spanish participants. According to physicians, 295 (29.0%) subjects were classified as high, and 723 (71.0%) as very high cardiovascular risk. Overall, 26.5% attained risk-based LDL-C targets recommended by 2019 European guidelines, with 23.1% of patients at high cardiovascular risk and 27.9% at very high cardiovascular risk. High-intensity statin therapy in monotherapy was used in 21.8%, LLT combination therapy in 41.2%, and 10.7% were not receiving any LLT. Baseline data from SANTORINI Spain population show that only about one-fourth of patients attain LDL-C targets recommended by the 2019 ESC/EAS guidelines in patients at high and very high risk. Despite their cardiovascular risk, patients appear to be not adequately treated, and high-intensity and combination LLT seem to be underused for cardiovascular disease prevention in the real-world setting. ClinicalTrials.gov Identifier: NCT04271280. Existen pocos estudios que hayan evaluado el tratamiento hipolipemiante (LLTs) y la consecución de objetivos de colesterol de lipoproteínas de baja densidad (C-LDL) después de la publicación de las guías de 2019 de la Sociedad Europea de Cardiología (ESC) y Aterosclerosis (EAS). Este manuscrito presenta los datos basales de la subpoblación española del estudio SANTORINI (denominado SANTORINI España) sobre la consecución de objetivos de LDL-C y el uso de LLTs en pacientes con riesgo cardiovascular alto y muy alto. SANTORINI fue un estudio multinacional, prospectivo y observacional que incluyó a pacientes con riesgo cardiovascular alto y muy alto de 14 países europeos en entornos de atención primaria y atención especializada. En el presente análisis se han analizado datos sociodemográficos, niveles de lípidos en sangre y tratamientos hipolipemiantes utilizados, en los 1018 participantes españoles, y se han puesto en perspectiva con la cohorte europea excluida la población española. Según el criterio de los médicos participantes, 295 (29,0%) pacientes fueron clasificados como de riesgo cardiovascular alto y 723 (71,0%) como de riesgo muy alto. Globalmente, el 26,5% alcanzó los objetivos de C-LDL recomendados por las guías europeas de 2019, un 23,1% de los pacientes con riesgo cardiovascular alto y un 27,9% de aquellos con riesgo cardiovascular muy alto. El tratamiento con estatinas de alta intensidad en monoterapia se utilizó en el 21,8%, la terapia combinada de hipolipemiantes en el 41,2%, y el 10,7% no recibió ningún LLT. Los datos basales de la población de SANTORINI España muestran que solo alrededor de una cuarta parte de los pacientes alcanza los objetivos de C-LDL recomendados por las guías ESC/EAS de 2019 en pacientes con riesgo cardiovascular alto y muy alto. A pesar de dicho riesgo, la utilización de tratamientos de alta intensidad y de tratamientos en combinación están infrautilizados. ClinicalTrials.gov: NCT04271280.</description><subject>Cardiovascular</subject><subject>Colesterol de lipoproteínas de baja densidad</subject><subject>España</subject><subject>Lipid-lowering therapy</subject><subject>Low-density lipoprotein cholesterol</subject><subject>Riesgo</subject><subject>Risk</subject><subject>SANTORINI</subject><subject>Spain</subject><subject>Terapia hipolipemiante</subject><issn>2254-8874</issn><issn>2254-8874</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kd1uEzEQhVcIRKvSJ0BCvuRmF4_X-xMkLqr0h0hRK9FybTn2OOuwWS_2OijPxQvWSQriiquZkb5zZuyTZe-BFkCh_rQpvMJhXTDKeAFQUMpfZeeMVTxv24a__qc_yy5D2FBKgcGsqunb7Kyc1VACpefZ71tp--iROEOW18t8TtZO9oFI1Vnc4RaHichBkzho9DEcud6OVue9-4XeDmsydejlaDEQO5BRTjZpksFEOrvujuId-v1pUtJr63YyqNhLT7wNPz6Tx1EONnQkxFXAiRjvtgdTchO9G1EO5PHq_unh2-J-QcIU9f5d9sakG_HypV5k329vnuZf8-XD3WJ-tcwVVJzmukWOdVWB5KwCUypJjeFNRYG2dNXMGChQlQaDlWSGS65pw1LTaF3PDGvKi-zjyXf07mfEMImtDQr7Xg7oYhAllLwsad1CQssTqrwLwaMRo7db6fcCqDgEJjbiGJg4BCYARAosqT68LIirLeq_mj_xJODLCcD0zJ1FL4JK36tQW49qEtrZ_y54Br8PqWc</recordid><startdate>20241128</startdate><enddate>20241128</enddate><creator>Mostaza, J.M.</creator><creator>García-Ortiz, L.</creator><creator>Suárez Tembra, M.A.</creator><creator>Talavera Calle, P.</creator><creator>Chimeno García, J.</creator><creator>Escolar Pérez, V.</creator><creator>Díaz-Díaz, J.L.</creator><creator>Manzano-Espinosa, L.</creator><creator>Catapano, A.L.</creator><creator>Ray, K.K.</creator><creator>Díaz Moya, G.</creator><creator>Pedro-Botet Montoya, J.</creator><general>Elsevier España, S.L.U</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241128</creationdate><title>Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study</title><author>Mostaza, J.M. ; García-Ortiz, L. ; Suárez Tembra, M.A. ; Talavera Calle, P. ; Chimeno García, J. ; Escolar Pérez, V. ; Díaz-Díaz, J.L. ; Manzano-Espinosa, L. ; Catapano, A.L. ; Ray, K.K. ; Díaz Moya, G. ; Pedro-Botet Montoya, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1540-d8e4e6551a4251f3ca0ff47501080b7921c1c5d1fe5a2f4a4d0722f47dd69f273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiovascular</topic><topic>Colesterol de lipoproteínas de baja densidad</topic><topic>España</topic><topic>Lipid-lowering therapy</topic><topic>Low-density lipoprotein cholesterol</topic><topic>Riesgo</topic><topic>Risk</topic><topic>SANTORINI</topic><topic>Spain</topic><topic>Terapia hipolipemiante</topic><toplevel>online_resources</toplevel><creatorcontrib>Mostaza, J.M.</creatorcontrib><creatorcontrib>García-Ortiz, L.</creatorcontrib><creatorcontrib>Suárez Tembra, M.A.</creatorcontrib><creatorcontrib>Talavera Calle, P.</creatorcontrib><creatorcontrib>Chimeno García, J.</creatorcontrib><creatorcontrib>Escolar Pérez, V.</creatorcontrib><creatorcontrib>Díaz-Díaz, J.L.</creatorcontrib><creatorcontrib>Manzano-Espinosa, L.</creatorcontrib><creatorcontrib>Catapano, A.L.</creatorcontrib><creatorcontrib>Ray, K.K.</creatorcontrib><creatorcontrib>Díaz Moya, G.</creatorcontrib><creatorcontrib>Pedro-Botet Montoya, J.</creatorcontrib><creatorcontrib>en representación del grupo de investigadores de SANTORINI España</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista clínica espanõla (English edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mostaza, J.M.</au><au>García-Ortiz, L.</au><au>Suárez Tembra, M.A.</au><au>Talavera Calle, P.</au><au>Chimeno García, J.</au><au>Escolar Pérez, V.</au><au>Díaz-Díaz, J.L.</au><au>Manzano-Espinosa, L.</au><au>Catapano, A.L.</au><au>Ray, K.K.</au><au>Díaz Moya, G.</au><au>Pedro-Botet Montoya, J.</au><aucorp>en representación del grupo de investigadores de SANTORINI España</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study</atitle><jtitle>Revista clínica espanõla (English edition)</jtitle><addtitle>Rev Clin Esp (Barc)</addtitle><date>2024-11-28</date><risdate>2024</risdate><issn>2254-8874</issn><eissn>2254-8874</eissn><abstract>There are very few studies evaluating lipid-lowering treatments (LLTs) and low-density lipoprotein-cholesterol (LDL-C) goal attainment after the release of the 2019 guidelines of the European Societies of Cardiology (ESC) and Atherosclerosis (EAS). This manuscript shows baseline data of the Spanish subset from SANTORINI study (namely SANTORINI Spain) on LDL-C goal attainment and use of LLTs in patients at high and very high cardiovascular risk. SANTORINI was a multinational, prospective, observational study involving patients at high and very high cardiovascular risk from 14 European countries in primary care and specialized healthcare settings. Sociodemographic data, blood lipid levels, and lipid treatments from the 1018 Spanish participants were separately analyzed and were put into perspective with the European cohort without Spanish participants. According to physicians, 295 (29.0%) subjects were classified as high, and 723 (71.0%) as very high cardiovascular risk. Overall, 26.5% attained risk-based LDL-C targets recommended by 2019 European guidelines, with 23.1% of patients at high cardiovascular risk and 27.9% at very high cardiovascular risk. High-intensity statin therapy in monotherapy was used in 21.8%, LLT combination therapy in 41.2%, and 10.7% were not receiving any LLT. Baseline data from SANTORINI Spain population show that only about one-fourth of patients attain LDL-C targets recommended by the 2019 ESC/EAS guidelines in patients at high and very high risk. Despite their cardiovascular risk, patients appear to be not adequately treated, and high-intensity and combination LLT seem to be underused for cardiovascular disease prevention in the real-world setting. ClinicalTrials.gov Identifier: NCT04271280. Existen pocos estudios que hayan evaluado el tratamiento hipolipemiante (LLTs) y la consecución de objetivos de colesterol de lipoproteínas de baja densidad (C-LDL) después de la publicación de las guías de 2019 de la Sociedad Europea de Cardiología (ESC) y Aterosclerosis (EAS). Este manuscrito presenta los datos basales de la subpoblación española del estudio SANTORINI (denominado SANTORINI España) sobre la consecución de objetivos de LDL-C y el uso de LLTs en pacientes con riesgo cardiovascular alto y muy alto. SANTORINI fue un estudio multinacional, prospectivo y observacional que incluyó a pacientes con riesgo cardiovascular alto y muy alto de 14 países europeos en entornos de atención primaria y atención especializada. En el presente análisis se han analizado datos sociodemográficos, niveles de lípidos en sangre y tratamientos hipolipemiantes utilizados, en los 1018 participantes españoles, y se han puesto en perspectiva con la cohorte europea excluida la población española. Según el criterio de los médicos participantes, 295 (29,0%) pacientes fueron clasificados como de riesgo cardiovascular alto y 723 (71,0%) como de riesgo muy alto. Globalmente, el 26,5% alcanzó los objetivos de C-LDL recomendados por las guías europeas de 2019, un 23,1% de los pacientes con riesgo cardiovascular alto y un 27,9% de aquellos con riesgo cardiovascular muy alto. El tratamiento con estatinas de alta intensidad en monoterapia se utilizó en el 21,8%, la terapia combinada de hipolipemiantes en el 41,2%, y el 10,7% no recibió ningún LLT. Los datos basales de la población de SANTORINI España muestran que solo alrededor de una cuarta parte de los pacientes alcanza los objetivos de C-LDL recomendados por las guías ESC/EAS de 2019 en pacientes con riesgo cardiovascular alto y muy alto. A pesar de dicho riesgo, la utilización de tratamientos de alta intensidad y de tratamientos en combinación están infrautilizados. ClinicalTrials.gov: NCT04271280.</abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>39613100</pmid><doi>10.1016/j.rceng.2024.11.004</doi></addata></record>
fulltext fulltext
identifier ISSN: 2254-8874
ispartof Revista clínica espanõla (English edition), 2024-11
issn 2254-8874
2254-8874
language eng
recordid cdi_proquest_miscellaneous_3134330681
source Alma/SFX Local Collection
subjects Cardiovascular
Colesterol de lipoproteínas de baja densidad
España
Lipid-lowering therapy
Low-density lipoprotein cholesterol
Riesgo
Risk
SANTORINI
Spain
Terapia hipolipemiante
title Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A06%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Failure%20of%20LDL-C%20goals%20achievement%20and%20underuse%20of%20lipid-lowering%20therapies%20in%20patients%20at%20high%20and%20very%20high%20cardiovascular%20risk:%20Spanish%20subset%20from%20the%20European%20SANTORINI%20study&rft.jtitle=Revista%20cl%C3%ADnica%20espan%C3%B5la%20(English%20edition)&rft.au=Mostaza,%20J.M.&rft.aucorp=en%20representaci%C3%B3n%20del%20grupo%20de%20investigadores%20de%20SANTORINI%20Espa%C3%B1a&rft.date=2024-11-28&rft.issn=2254-8874&rft.eissn=2254-8874&rft_id=info:doi/10.1016/j.rceng.2024.11.004&rft_dat=%3Cproquest_cross%3E3134330681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3134330681&rft_id=info:pmid/39613100&rft_els_id=S2254887424001504&rfr_iscdi=true